Menu Search
Equities

Cipla Ltd

CIPLA:NSI

Cipla Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,592.60
  • Today's Change9.85 / 0.62%
  • Shares traded1.72m
  • 1 Year change+28.44%
  • Beta0.4440
Data delayed at least 15 minutes, as of Nov 08 2024 10:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Cipla Ltd grew revenues 13.28% from 227.53bn to 257.74bn while net income improved 47.10% from 28.02bn to 41.22bn.
Gross margin67.01%
Net profit margin16.92%
Operating margin20.48%
Return on assets13.58%
Return on equity16.83%
Return on investment16.44%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Cipla Ltd fell by 489.90m. However, the company earned 41.34bn from its operations for a Cash Flow Margin of 16.04%. In addition the company used 29.88bn on investing activities and also paid 12.00bn in financing cash flows.
Cash flow per share68.40
Price/Cash flow per share23.28
Book value per share351.20
Tangible book value per share287.92
More ▼

Balance sheet in INRView more

Cipla Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 1.60%.
Current ratio3.84
Quick ratio2.82
Total debt/total equity0.0163
Total debt/total capital0.016
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 52.94% and 47.16%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)0.74%
Div growth rate (5 year)34.08%
Payout ratio (TTM)23.45%
EPS growth(5 years)21.94
EPS (TTM) vs
TTM 1 year ago		29.53
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.